Company / Capital Expenditures
Eloxx Pharmaceuticals, Inc. Capital Expenditures History
FY2014-FY2016 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$3.2K
FY2016
5-year range
$1.3K / $4.5K
FY2014-FY2016
Trend
+149.3%
vs FY2015
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $4,461 to $3,194 over the past 2 years.
Based on SEC 10-K filings.
$3,194 in FY2016.
Declined from $4,461 to $3,194 over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2016, capital expenditures increased 149.3% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -40.59 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2016 | $3.2K | +149.3% |
| FY2015 | $1.3K | -71.3% |
| FY2014 | $4.5K | - |
As of FY2016 · SEC 10-K · Updated Jun 24, 2026